AR059300A1 - Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas - Google Patents

Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas

Info

Publication number
AR059300A1
AR059300A1 ARP070100450A ARP070100450A AR059300A1 AR 059300 A1 AR059300 A1 AR 059300A1 AR P070100450 A ARP070100450 A AR P070100450A AR P070100450 A ARP070100450 A AR P070100450A AR 059300 A1 AR059300 A1 AR 059300A1
Authority
AR
Argentina
Prior art keywords
seq
hiv fusion
biological properties
improved biological
inhibiting peptides
Prior art date
Application number
ARP070100450A
Other languages
English (en)
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of AR059300A1 publication Critical patent/AR059300A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Abstract

Se provee un péptido inhibidor de fusion de HIV con una secuencia de aminoácidos de cualquiera de SEQ ID N°:9, SEQ ID N°:10, SEQ ID N°:11, SEQ ID N°:12, SEQ ID N°:13, SEQ ID N°:14, o SEQ ID N°:15; y se provee una composicion farmacéutica que comprende un péptido inhibidor de fusion de HIV y uno o más de un portador farmacéuticamente aceptable y portador macromolecular, y los usos y métodos de tratamiento provisto por estas composiciones. Reivindicacion 5: Un vector caracterizado porque comprende la molécula de ácido nucleico de acuerdo con la reivindicacion 4. Reivindicacion 7: Una célula aislada caracterizada porque comprende el vector de acuerdo con la reivindicacion 5 o 6.
ARP070100450A 2006-02-02 2007-02-02 Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas AR059300A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76467406P 2006-02-02 2006-02-02

Publications (1)

Publication Number Publication Date
AR059300A1 true AR059300A1 (es) 2008-03-26

Family

ID=38437849

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070100450A AR059300A1 (es) 2006-02-02 2007-02-02 Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
ARP170101125A AR108277A2 (es) 2006-02-02 2017-05-02 Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170101125A AR108277A2 (es) 2006-02-02 2017-05-02 Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas

Country Status (15)

Country Link
US (3) US7456251B2 (es)
EP (1) EP1989220B1 (es)
JP (1) JP4682251B2 (es)
CN (1) CN101415723B (es)
AR (2) AR059300A1 (es)
AT (1) ATE537183T1 (es)
AU (1) AU2007218025A1 (es)
CA (1) CA2651793C (es)
CY (1) CY1113115T1 (es)
DK (1) DK1989220T3 (es)
ES (1) ES2381631T3 (es)
NZ (1) NZ570300A (es)
PT (1) PT1989220E (es)
TW (1) TWI341844B (es)
WO (1) WO2007097903A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI341844B (en) 2006-02-02 2011-05-11 Trimeris Inc Hiv fusion inhibitor peptides with improved biological properties
KR20100080812A (ko) * 2007-09-25 2010-07-12 트라이머리스, 인코퍼레이티드 치료용 항-ｈｉｖ 펩티드의 합성 방법
CA2724900A1 (en) * 2008-05-28 2009-12-23 New York Blood Center Bifunctional molecules for inhibiting hiv entry
EP2321342A2 (en) * 2008-08-13 2011-05-18 New York Blood Center Combination therapy of hiv fusion/entry inhibitors targeting gp41
US8936789B2 (en) * 2008-10-16 2015-01-20 New York Bood Center, Inc. Immunoenhancer-linked oligomeric HIV envelope peptides
WO2010047826A2 (en) * 2008-10-24 2010-04-29 Trimeris, Inc. Dosing regimens and dosage formulations of an antiviral peptide therapeutic
CA2751865A1 (en) * 2009-02-09 2010-08-12 New York Blood Center, Inc. Trimeric hiv fusion inhibitors for treating or preventing hiv infection
AU2011248279A1 (en) 2010-05-03 2012-11-01 New York Blood Center, Inc. Bifunctional molecules for inactivating HIV and blocking HIV
WO2013092591A1 (en) * 2011-12-19 2013-06-27 Janssen R&D Ireland Hiv membrane fusion inhibitors
EP2834264A1 (en) 2012-04-04 2015-02-11 Yeda Research and Development Co. Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
CN103724404B (zh) * 2013-12-08 2016-11-02 北京工业大学 抑制hiv病毒与宿主细胞融合的非对映体多肽及其用途
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CN109320593A (zh) * 2018-11-05 2019-02-12 中国人民解放军军事科学院军事医学研究院 抑制hiv感染的螺旋多肽及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016273A (en) 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
JPS55154991A (en) 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5234520A (en) 1987-03-20 1993-08-10 Morgan Adhesives Co. Method of making an adhesive construction
CN1030256A (zh) * 1987-06-29 1989-01-11 日清食品株式会社 检测和治疗人类免疫缺陷病毒的方法和物质
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5462863A (en) 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
WO1993007603A1 (en) 1991-10-04 1993-04-15 Cornett Robert H Approaching emergency vehicle warning system
CA2140663C (en) 1992-07-20 2004-01-27 Carl T. Wild Compounds which inhibit hiv replication
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
ES2153418T3 (es) 1993-02-23 2001-03-01 Genentech Inc Estabilizacion de polipeptidos tratados con solventes organicos por medio de excipientes.
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
WO1996040191A1 (en) 1995-06-07 1996-12-19 Trimeris, Inc. The treatment of hiv and other viral infections using combinatory therapy
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
US6919372B1 (en) 1997-12-26 2005-07-19 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical compositions
JPH11209456A (ja) * 1998-01-29 1999-08-03 Hitachi Chem Co Ltd 印刷配線板用難燃性エポキシ樹脂組成物及びこれを用いたプリプレグ、金属箔張り積層板
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
DE60000665T3 (de) 1999-05-17 2009-10-29 ConjuChem Biotechnologies Inc., Montreal Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
AU2001259111B2 (en) 2000-04-19 2005-12-08 Durect Corporation Sustained release formulations comprising growth hormone
DK1397155T3 (en) 2001-06-21 2015-12-07 Genentech Inc Prolonged release formulation
CN1100564C (zh) 2001-08-29 2003-02-05 周根发 用于治疗hiv感染的药物、其组合物及其用途
US7045552B2 (en) 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
JP2007517522A (ja) * 2004-01-07 2007-07-05 トリメリス，インコーポレーテッド ＨＩＶｇｐ４１ＨＲ２由来の合成ペプチド、およびヒト免疫不全ウイルスの伝播を阻止する治療におけるその使用
CA2556032A1 (en) * 2004-03-15 2005-09-29 Trimeris, Inc. Site-specific chemical modification of hiv gp41-derived peptides
CN101132812A (zh) 2004-03-15 2008-02-27 阿拉巴马耐科塔医药公司 Hiv进入抑制剂的聚合物基组合物和结合物
TWI341844B (en) 2006-02-02 2011-05-11 Trimeris Inc Hiv fusion inhibitor peptides with improved biological properties

Also Published As

Publication number Publication date
NZ570300A (en) 2011-08-26
AU2007218025A1 (en) 2007-08-30
WO2007097903A3 (en) 2008-05-22
CA2651793A1 (en) 2007-08-30
US20120040891A1 (en) 2012-02-16
DK1989220T3 (da) 2012-04-02
CN101415723B (zh) 2014-06-25
CN101415723A (zh) 2009-04-22
AR108277A2 (es) 2018-08-01
ES2381631T3 (es) 2012-05-30
CA2651793C (en) 2015-07-07
TW200806687A (en) 2008-02-01
PT1989220E (pt) 2012-03-23
US7456251B2 (en) 2008-11-25
ATE537183T1 (de) 2011-12-15
TWI341844B (en) 2011-05-11
EP1989220B1 (en) 2011-12-14
US20070179278A1 (en) 2007-08-02
EP1989220A2 (en) 2008-11-12
US8034899B2 (en) 2011-10-11
US20090105143A1 (en) 2009-04-23
EP1989220A4 (en) 2009-05-06
JP4682251B2 (ja) 2011-05-11
WO2007097903A2 (en) 2007-08-30
CY1113115T1 (el) 2016-04-13
JP2009525051A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
PE20161325A1 (es) L-asparaginasa tratada con peg
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
MX2009012609A (es) Composiciones y metodos para producir proteinas de fusion bioactivas.
BR112012011740A2 (pt) polipeptídeo, composição compreendendo o referido polipeptídeo, complexo de proteína, seqüência de nucleotídeo, vetor de expressão célula, e métodos para a preparação do complexo de proteína, para a preparação de um fviii, e para intensificar uma propriedade farmacocinética no plasma de um fviii
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
EP2573109A3 (en) Peptide vaccines comprising Seq Id 101, 80 or 100 for cancers expressing tumor-associated antigens
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
NZ704191A (en) Cell-penetrating peptides and uses therof
PE20120021A1 (es) Mutantes fgf21
ES2683372T3 (es) Derivados de GLP-1 acilados con un conector nuevo
Takagi et al. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity
PE20120425A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
NZ708990A (en) Method for activating helper t cell
WO2010034105A8 (en) Hepatitis c inhibitor compounds
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
AR030278A1 (es) Peptido modulador del receptor de trombopoyetina
MX2009007261A (es) Vacuna de peptido foxp3.
ECSP11010938A (es) Transferasa glucuronilo y un polinucleótido que codifica el mismo
IN2014DN09963A (es)
MX2010005816A (es) Epítopos de péptido de stat3.

Legal Events

Date Code Title Description
FG Grant, registration